253 related articles for article (PubMed ID: 25213362)
1. Anti-CD20 antibody in primary Sjögren's syndrome management.
Chen S; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
[TBL] [Abstract][Full Text] [Related]
2. B-cell populations and sub-populations in Sjögren's syndrome.
Hamza N; Bos NA; Kallenberg CG
Presse Med; 2012 Sep; 41(9 Pt 2):e475-83. PubMed ID: 22841377
[TBL] [Abstract][Full Text] [Related]
3. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
4. Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?
Meiners PM; Vissink A; Kallenberg CG; Kroese FG; Bootsma H
Expert Opin Biol Ther; 2011 Oct; 11(10):1381-94. PubMed ID: 21819314
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in primary Sjögren's syndrome: a ten-year journey.
Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
[TBL] [Abstract][Full Text] [Related]
7. Biologic treatments in Sjögren's syndrome.
Bowman S; Barone F
Presse Med; 2012 Sep; 41(9 Pt 2):e495-509. PubMed ID: 22836195
[TBL] [Abstract][Full Text] [Related]
8. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.
Alunno A; Carubbi F; Bistoni O; Caterbi S; Bartoloni E; Di Benedetto P; Cipriani P; Giacomelli R; Gerli R
Clin Exp Immunol; 2016 Jun; 184(3):284-92. PubMed ID: 26814615
[TBL] [Abstract][Full Text] [Related]
9. NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.
Pontarini E; Sciacca E; Grigoriadou S; Rivellese F; Lucchesi D; Fossati-Jimack L; Coleby R; Chowdhury F; Calcaterra F; Tappuni A; Lewis MJ; Fabris M; Quartuccio L; Bella SD; Bowman S; Pitzalis C; Mavilio D; De Vita S; Bombardieri M
Front Immunol; 2021; 12():706737. PubMed ID: 34594326
[TBL] [Abstract][Full Text] [Related]
10. [First experience with the application of rituximab for the treatment of patients with Sjogren's syndrome and disease].
Vasil'ev VI; Logvinenko OA; Kokosadze NV; Gaĭduk IV; Varlamova EIu; Kovrigina AM; Gorodetskiĭ VR; Nasonov EL
Vestn Ross Akad Med Nauk; 2009; (2):3-10. PubMed ID: 19283903
[TBL] [Abstract][Full Text] [Related]
11. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
Atzeni F; Sarzi-Puttini P
Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
[No Abstract] [Full Text] [Related]
12. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
Saraux A
Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
[TBL] [Abstract][Full Text] [Related]
13. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.
Brown S; Navarro Coy N; Pitzalis C; Emery P; Pavitt S; Gray J; Hulme C; Hall F; Busch R; Smith P; Dawson L; Bombardieri M; Wan-Fai N; Pease C; Price E; Sutcliffe N; Woods C; Ruddock S; Everett C; Reynolds C; Skinner E; Poveda-Gallego A; Rout J; Macleod I; Rauz S; Bowman S;
BMC Musculoskelet Disord; 2014 Jan; 15():21. PubMed ID: 24438039
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
15. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
16. B-cell depletion and repopulation in autoimmune diseases.
Pers JO; Daridon C; Bendaoud B; Devauchelle V; Berthou C; Saraux A; Youinou P
Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 treatment in primary Sjögren's syndrome.
Isaksen K; Jonsson R; Omdal R
Scand J Immunol; 2008 Dec; 68(6):554-64. PubMed ID: 19000095
[TBL] [Abstract][Full Text] [Related]
18. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
St Clair EW; Levesque MC; Prak ET; Vivino FB; Alappatt CJ; Spychala ME; Wedgwood J; McNamara J; Moser Sivils KL; Fisher L; Cohen P;
Arthritis Rheum; 2013 Apr; 65(4):1097-106. PubMed ID: 23334994
[TBL] [Abstract][Full Text] [Related]
19. Primary Sjogren's syndrome: current and prospective therapies.
Thanou-Stavraki A; James JA
Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
[TBL] [Abstract][Full Text] [Related]
20. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
Abdulahad WH; Kroese FG; Vissink A; Bootsma H
J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
